Your browser doesn't support javascript.
loading
Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension.
Baron, Morgane; Maillet, Julie; Huyvaert, Marlène; Dechaume, Aurélie; Boutry, Raphaël; Loiselle, Hélène; Durand, Emmanuelle; Toussaint, Bénédicte; Vaillant, Emmanuel; Philippe, Julien; Thomas, Jérémy; Ghulam, Amjad; Franc, Sylvia; Charpentier, Guillaume; Borys, Jean-Michel; Lévy-Marchal, Claire; Tauber, Maïthé; Scharfmann, Raphaël; Weill, Jacques; Aubert, Cécile; Kerr-Conte, Julie; Pattou, François; Roussel, Ronan; Balkau, Beverley; Marre, Michel; Boissel, Mathilde; Derhourhi, Mehdi; Gaget, Stefan; Canouil, Mickaël; Froguel, Philippe; Bonnefond, Amélie.
Afiliação
  • Baron M; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Maillet J; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Huyvaert M; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Dechaume A; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Boutry R; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Loiselle H; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Durand E; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Toussaint B; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Vaillant E; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Philippe J; CNRS UMR 8199, European Genomic Institute for Diabetes, Institut Pasteur de Lille, University of Lille, Lille, France.
  • Thomas J; Center for Human Disease Modeling, Duke University Medical Center, Durham, NC, USA.
  • Ghulam A; Laboratoire de Biochimie et Hormonologie, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire, Lille, France.
  • Franc S; Laboratoire de Biochimie et Hormonologie, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire, Lille, France.
  • Charpentier G; CERITD (Centre d'Étude et de Recherche pour l'Intensification du Traitement du Diabète), Evry, France.
  • Borys JM; Department of Diabetes, Sud-Francilien Hospital, University Paris-Sud, Orsay, Corbeil-Essonnes, France.
  • Lévy-Marchal C; CERITD (Centre d'Étude et de Recherche pour l'Intensification du Traitement du Diabète), Evry, France.
  • Tauber M; Department of Diabetes, Sud-Francilien Hospital, University Paris-Sud, Orsay, Corbeil-Essonnes, France.
  • Scharfmann R; Fleurbaix Laventie Association, Laventie, France.
  • Weill J; Department of Clinical Epidemiology, Inserm CIE 05, Robert Debré Hospital, Paris, France.
  • Aubert C; Endocrinology, Obesity, Bone Disease, Genetics and Medical Gynecology, Hôpital des Enfants, Inserm UMR 1043, Université Toulouse III-Paul Sabatier, Toulouse, France.
  • Kerr-Conte J; Inserm U1016, Institut Cochin, Université Paris Descartes, Paris, France.
  • Pattou F; Pediatric Endocrine Department, Lille Hospital, Lille, France.
  • Roussel R; Ildys Foundation, Roscoff, France.
  • Balkau B; Inserm U1190, EGID, CHU Lille, University of Lille, Lille, France.
  • Marre M; Inserm U1190, EGID, CHU Lille, University of Lille, Lille, France.
  • Boissel M; Department of Diabetology, Endocrinology and Nutrition, Hôpital Bichat, DHU FIRE, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Derhourhi M; Inserm U1138, Centre de Recherche des Cordeliers, Paris, France.
  • Gaget S; UFR de Médecine, University Paris Diderot, Sorbonne Paris Cité, Paris, France.
  • Canouil M; Inserm U1018, Center for Research in Epidemiology and Population Health, Villejuif, France.
  • Froguel P; University Paris-Saclay, University Paris-Sud, Villejuif, France.
  • Bonnefond A; Inserm U1138, Centre de Recherche des Cordeliers, Paris, France.
Nat Med ; 25(11): 1733-1738, 2019 11.
Article em En | MEDLINE | ID: mdl-31700171
The G-protein-coupled receptor accessory protein MRAP2 is implicated in energy control in rodents, notably via the melanocortin-4 receptor1. Although some MRAP2 mutations have been described in people with obesity1-3, their functional consequences on adiposity remain elusive. Using large-scale sequencing of MRAP2 in 9,418 people, we identified 23 rare heterozygous variants associated with increased obesity risk in both adults and children. Functional assessment of each variant shows that loss-of-function MRAP2 variants are pathogenic for monogenic hyperphagic obesity, hyperglycemia and hypertension. This contrasts with other monogenic forms of obesity characterized by excessive hunger, including melanocortin-4 receptor deficiency, that present with low blood pressure and normal glucose tolerance4. The pleiotropic metabolic effect of loss-of-function mutations in MRAP2 might be due to the failure of different MRAP2-regulated G-protein-coupled receptors in various tissues including pancreatic islets.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperfagia / Predisposição Genética para Doença / Proteínas Adaptadoras de Transdução de Sinal / Obesidade Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperfagia / Predisposição Genética para Doença / Proteínas Adaptadoras de Transdução de Sinal / Obesidade Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article